Cyclophosphamide Infusion Research Articles

Intra Arterial Infusion of Cyclophosphamide in Oral Carcinoma

SummaryNinteen cases of advanced oral carcinoma were treated by continuous intraaterial infusion by cyclophosphamide. A newer technique by using Evan's Blue dye for visualizing the arterial supply was used and was found effective as the colour disappeared after a few minutes.The response to the therapy has been evaluated and results are presented. In three patients the disease was brought to the point where surgery could be per-formed resulting in long term freedom from disease.

Cyclophosphamide-induced changes in circulating lymphocyte kinetics in chronic lymphocytic leukemia.

The effects of cyclophosphamide upon circulating lymphocytes were studied in 3 patients with chronic lymphocytic leukemia using autologous lymphocytes labelled with Na251 CrO4. Blood and organ radioactivity were studied before therapy, and the results compared with those obtained while each patient was receiving weekly intravenous infusions of cyclophosphamide. Two patients manifested clinical and laboratory evidence of response to the drug. In one of these patients, there was a comparatively greater loss of circulating radioactivity within a few days after the first dose. In the other, the initial curve appeared unchanged while there was increased loss of circulating activity after the first week. There was a relative increase in hepatic radioactivity during therapy in both patients. The third patient did not appear to respond to cyclophosphamide, and only a minimal difference in his lymphocyte kinetics was found during therapy. These observations indicate that the response of circulating lymphocytes to cyclophosphamide may vary in different patients with chronic lymphocytic leukemia, and that the loss of circulating radioactivity is associated with increased hepatic uptake of label.

Chemotherapy for Lung Cancer by Intra-aortic Infusion

Over a period of four years, 91 patients with inoperable or nonresectable lung cancer (55 bronchogenic and 36 metastatic) were treated by the continuous regional intra-aortic infusion of fluorouracil and cyclophosphamide, or both, for the purpose of increasing and prolonging the concentration of these agents in tumor-bearing areas supplied by the bronchial arteries. Twelve of the patients with bronchogenic cancer showed an objective response rate of 12.4 months' duration with an average survival time of 13.4 months. In the metastatic group, the cancers of 12 patients had an average objective regression of 12.5 months' duration with an average survival time of 14.5 months. A comparable retrospective study of the intravenous method of administration demonstrated no objective response (by our criteria) in 49 cases of bronchogenic and seven cases of metastatic lung cancer. Average survival time was 4.2 and 4.4 months, respectively.

Proposal of classification and therapeutic criteria of lymphosarcoma and reticulosarcoma

Proposal of classification and therapeutic criteria of lymphosarcoma and reticulosarcoma

THE TREATMENT OF HEAD AND NECK CANCER BY INTRA-ARTERIAL INFUSION

Though chemotherapeutic agents have greatly improved, antitumor drugs play a minor role compared to irradiation or operation in the treatment of malignant diseases. While producing a specific antitumor effect, these drugs show the toxicity on normal structures. For this reason attempts have been made to minimize the systemic toxicity of antitumor drugs on normal tissues and to obtain the maximum concentration in tumor areas. Based on these ideas. Klopp et al (1950) first introduced the intra-arterial administration of cytotoxic agents' We have managed twenty-two patients of the head and neck tumors, undergoing intra-arterial infusion of cyclo-phosphamide (Endoxan) or chromomycin A3 (Toyomycin). The superficial temporal artery or facial artery was catheterized, by inserting polyethylene tube of appropriate size until the tip of the tube was placed in the external carotid stream.The drug was injected continuously through the catheter. The results obtained show that six patients received significant regression and in twelve the tumor regressed partially. The intra-arterial infusion of Endoxan or To-yomycin may prove to be an important adjunct not only in the management of incurable head and neck tumors, but also as a pre-operative therapy for early stages of cancer.